Here's What Analysts Are Forecasting For Hansoh Pharmaceutical Group Company Limited (HKG:3692) After Its Half-Year Results
Shareholders of Hansoh Pharmaceutical Group Company Limited (HKG:3692) will be pleased this week, given that the stock price is up 11% to HK$36.72 following its latest half-yearly results. It was a workmanlike result, with revenues of CN¥8.3b coming in 3.4% ahead of expectations, and statutory earnings per share of CN¥0.93, in line with analyst appraisals. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
After the latest results, the 23 analysts covering Hansoh Pharmaceutical Group are now predicting revenues of CN¥17.0b in 2026. If met, this would reflect a satisfactory 6.9% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to decrease 4.9% to CN¥1.05 in the same period. In the lead-up to this report, the analysts had been modelling revenues of CN¥16.9b and earnings per share (EPS) of CN¥0.98 in 2026. So the consensus seems to have become somewhat more optimistic on Hansoh Pharmaceutical Group's earnings potential following these results.
See our latest analysis for Hansoh Pharmaceutical Group
The consensus price target was unchanged at HK$47.28, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Hansoh Pharmaceutical Group, with the most bullish analyst valuing it at HK$52.72 and the most bearish at HK$37.24 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Hansoh Pharmaceutical Group shareholders.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that Hansoh Pharmaceutical Group's rate of growth is expected to accelerate meaningfully, with the forecast 14% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 11% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 9.8% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Hansoh Pharmaceutical Group is expected to grow much faster than its industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Hansoh Pharmaceutical Group following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at HK$47.28, with the latest estimates not enough to have an impact on their price targets.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Hansoh Pharmaceutical Group analysts - going out to 2028, and you can see them free on our platform here.
You can also see our analysis of Hansoh Pharmaceutical Group's Board and CEO remuneration and experience, and whether company insiders have been buying stock.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.